Inspire Medical Systems, Inc.
No enriched coverage for $INSP in the last 7 days.
No SEC Form 4 filings for $INSP in the last 30 days.
See all $INSP insider activity →Inspire Semiconductor Holdings Inc. (InspireSemi) completed its redomicile from British Columbia to Delaware, converting all proportionate voting shares to subordinate voting shares. The move was approved by 99.59% of shareholders and aims to align the company with its U.S. base and simplify its capital structure. The company now has 473,556,246 shares of common stock outstanding.
STAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.
Inspire Medical Systems (INSP) reported a 7.6% revenue decline to $200.6M in Q2, with US sales driving the drop. Despite this, the company boasts an 85.5% gross margin, $415.2M in cash, and raised 2026 revenue guidance to $835M-$875M. The AMA approved new billing codes for its Inspire V system, a key reimbursement milestone. However, the stock trades at a high forward P/E of 59.17, reflecting investor optimism about future earnings.
Recent INSP coverage spans regulation, earnings and corporate actions.
Domestication and share-class conversion can change trading mechanics and investor perception, but it is not an operating or earnings catalyst.
Despite revenue decline, the earnings beat drove a sizable rally, reflecting optimism about guidance and product outlook.
The code approval may lift the stock as investors price in better reimbursement prospects.
Long‑term reimbursement clarity may support revenue growth, but near‑term impact limited.
Analyst upgrade with a higher price target may generate modest buying pressure.
AlphAI scores every news story that mentions INSP with an AI model for sentiment and relevance, and aggregates insider trades from Inspire Medical Systems, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Inspire Semiconductor Holdings Inc. (InspireSemi) completed its redomicile from British Columbia to Delaware, converting all proportionate voting shares to subordinate voting shares. The move was approved by 99.59% of shareholders and aims to align the company with its U.S. base and simplify its capital structure. The company now has 473,556,246 shares of common stock outstanding.
4 min readSTAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.
4 min readInspire Medical Systems (INSP) reported a 7.6% revenue decline to $200.6M in Q2, with US sales driving the drop. Despite this, the company boasts an 85.5% gross margin, $415.2M in cash, and raised 2026 revenue guidance to $835M-$875M. The AMA approved new billing codes for its Inspire V system, a key reimbursement milestone. However, the stock trades at a high forward P/E of 59.17, reflecting investor optimism about future earnings.
3 min readInspire Medical Systems (INSP) announced that the AMA CPT Editorial Panel approved new Category I CPT codes for its Inspire V sleep apnea system, effective January 1, 2028. These codes may improve long-term reimbursement clarity and provider workflows. Analysts expect revenue of $991.6M and earnings of $74.2M by 2029, with some optimistic views projecting higher figures. The company's near-term performance depends on center training, contracting, and coding education.
2 min readFreedom Capital Markets kept a Buy rating on Inspire Medical Systems with a $97 price target, suggesting 37% upside from the Oct 1 close. The firm cited new CPT code approvals for the Inspire V procedure, which should boost sales growth and investor confidence. The company's focus on physician education and untapped market potential supports the positive outlook.
1 min readInspire Medical Systems (INSP) announced new CPT codes for its Inspire V sleep apnea device, effective January 1, 2028. The codes describe implantation procedures. CMS will determine Medicare payment values, with proposed valuations expected in July 2027. The device is FDA-approved and has treated over 140,000 patients.
1 min readInspire Medical Systems (INSP) announced AMA CPT Editorial Panel approval for new Category I CPT codes covering its Inspire V system. Valuations are expected in 2027, with codes effective January 1, 2028. The approval supports reimbursement clarity and adoption trends for the next-gen system, according to the company.
1 min readInspire Medical Systems (INSP) announced the AMA approved new CPT codes for its Inspire V system, effective January 1, 2028. The company expects this to streamline reimbursement and expand patient access. CMS will determine Medicare payments for the new codes, with proposed valuations expected in July 2027 and final valuations in November 2027.
2 min readU.S. stocks ended slightly lower Wednesday as long bond yields rose, but Inspire Medical Systems (INSP) surged 18.95% month-to-date. The medical device company reported Q2 FY2026 earnings beating expectations, with EPS at $0.14 vs. -$0.24 consensus and revenue at $200.6M vs. $194.7M forecast. The stock has climbed 86% since March 2026, driven by strong fundamentals and improving reimbursement trends.
2 min readInspire Medical Systems (INSP) stock is falling due to a 46% year-over-year drop in net income, 7.6% lower revenue, and a projected 71% earnings decline next quarter. Rising costs are squeezing profit margins, raising investor concerns about the company's ability to stabilize earnings. Despite low debt and strong cash flow, insurance reimbursement issues pose risks to future performance.
2 min read
